title: [Impact of new therapeutic options in COPD].
authors.affiliation: Institut del Tòrax. Hospital Clínic, Universidad de Barcelona. CIBER Enfermedades Respiratorias (CIBERES). Fundación Caubet-Cimera. Mallorca. España.
authors.forename: Alvar
authors.initials: A
authors.lastname: Agustí
mesh_terms: D000631:Aminopyridines / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D003521:Cyclopropanes / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D058988:Phosphodiesterase 4 Inhibitors / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000517:prevention & control / Q000601:surgery; D016540:Smoking Cessation
chemical_list: D000631:Aminopyridines; D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D001549:Benzamides; D003521:Cyclopropanes; D015507:Drugs, Investigational; D058988:Phosphodiesterase 4 Inhibitors; C424423:Roflumilast